Form 4: Ionis Pharmaceuticals Director Loscalzo Receives Stock Options and Restricted Stock Units

Director Joseph Loscalzo receives stock options and restricted stock units from Ionis Pharmaceuticals as part of the company's non-employee director compensation policy.

Summary

• Joseph Loscalzo, a director at Ionis Pharmaceuticals, received stock options and restricted stock units (RSUs) on July 1, 2024.
• The grants were adjusted to ensure that the director's annual equity compensation does not exceed $450,000.
• Loscalzo received 10,111 non-qualified stock options with an exercise price of $47.11, which vest on the first anniversary of the grant date or the next annual meeting, expiring on June 30, 2034.
• He also received 4,079 restricted stock units, which vest on the first anniversary of the grant date or the next annual meeting and will be delivered on July 15th following the vesting date.
• Following these transactions, Loscalzo directly owns 10,111 derivative securities and 8,756 shares of common stock via restricted stock units.

Sentiment

Score: 7

Explanation: The document reflects a routine equity grant to a director, indicating standard corporate governance practices. The adjusted grant size suggests a focus on cost management, which is moderately positive.

Positives

• The equity grants align the director's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Future Outlook

The director's equity grants are subject to vesting conditions, aligning their interests with the company's long-term performance.

Industry Context

Equity compensation is a common practice for directors of publicly traded companies to align their interests with shareholders and incentivize long-term value creation.

Comparison to Industry Standards

• Director compensation packages vary widely across the pharmaceutical industry, depending on company size, performance, and board structure.
• Comparing Ionis Pharmaceuticals' director compensation to companies like Alnylam Pharmaceuticals or Biogen would provide a better understanding of its relative competitiveness.
• The $450,000 annual equity compensation limit appears to be within the typical range for non-executive directors at similarly sized biotech companies.

Stakeholder Impact

• The equity grants align the director's interests with those of the shareholders, potentially leading to better decision-making.
• Employees may view the equity grants as a positive sign of the company's commitment to its leadership.

Key Dates